A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 Sep 2019
Price : $35 *
At a glance
- Drugs Roxadustat (Primary) ; Darbepoetin alfa; Darbepoetin alfa
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms Dolomites
- Sponsors Astellas Pharma Europe Ltd
- 24 Sep 2019 This trial has been completed in Portugal, according to European Clinical Trials Database record.
- 30 Oct 2018 Planned End Date changed from 1 Oct 2019 to 1 Nov 2019.
- 31 Aug 2018 Biomarkers information updated